IL22 and inflammatory bowel disease: Characterizing the impact increased IL-22 activity has on the microbiome is essential to understanding the therapeutic value of exogenous IL-22 treatment, especially in a disease setting such as IBD where microbial dysbiosis is a defining feature [26, 27].